OncoLogue™ - Program Overview
To begin this program, please choose a participation option at the bottom of this page.
Clinical Updates on Maintenance Therapy for NSCLC
PROGRAM 2 of 2
Optimizing Maintenance Therapy for Patients With Advanced Non–Small-Cell Lung Cancer
Approved for AMA PRA Category 1 Credit(s)™
UPDATE: Your Selected Questions
In this program, we had asked participants to submit questions to the faculty about the material. The selected questions are now available to view. Expert responses to these questions will be provided at a later date.
The 2 major maintenance trials presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) examined “continuation maintenance” therapy, while the approved agents were investigated in the context of “switch maintenance” therapy. Which approach would you recommend outside a clinical trial?
While one phase III trial of maintenance gemcitabine reported a significant PFS benefit at ASCO 2010, another phase III trial of maintenance gemcitabine did not. Why do you think that different outcomes were observed in these 2 trials?
Should maintenance pemetrexed be administered to a patient who received first-line pemetrexed plus platinum?
Maintenance pemetrexed is a reasonable option for patients with nonsquamous NSCLC. Would maintenance pemetrexed plus platinum be better?
Should patients be tested for EGFR mutation status if erlotinib is being considered as maintenance therapy in advanced NSCLC? What about KRAS mutation status?
How do you select patients who are good candidates to receive maintenance therapy and who should be offered a treatment break with close monitoring for disease progression? Is quality of life and/or toxicity a factor in your decision making?
Upon completion of this educational activity, you should be able to:
- Evaluate clinical data on continuation maintenance following frontline treatment in advanced NSCLC
- Assess the efficacy of switch maintenance using active second-line agents in patients with advanced NSCLC
- Choose the optimal maintenance therapy for individual patients with advanced NSCLC based on tumor characteristics
Choose a Participation Option
To claim credit for this activity you must:
- Participate in the Activity
- Claim your Credit Amount & Certificate Type
If you do not wish to claim credit:
You may bypass all CE information, tests and evaluations and go straight to the activity.
You may not request credit after viewing the activity.
I wish to participate in this
activity and claim credit.
I wish to view the activity
without claiming credit.
What is OncoLogue?Viewing: Program 2 of 2
-
Program 1 of 2Practical Considerations in Selecting Patients to Receive Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
-
Program 2 of 2Optimizing Maintenance Therapy for Patients With Advanced Non–Small-Cell Lung Cancer